Oxford

London's Telegraph reports that results from a Phase 1 clinical trial evaluating Oxford University's COVID-19 vaccine candidate ChAdOx1 nCoV-19 [ADZ1222 by licensee AstraZeneca (NYSE:AZN)] in healthy volunteers showed that it triggered a "double defense" immune response against the SARS-CoV-2 virus. Researchers noted that administration of the candidate produced both antibodies and killer T cells. The…

Oxford University's coronavirus vaccine project leader isn't as enthusiastic as you want him to be. Clinical trial results from an experimental coronavirus vaccine AstraZeneca (NYSE:AZN) licensed from Oxford University might not be ready this September as hoped. In an interview with The Telegraph, the director of Oxford's Jenner Institute, Professor Adrian Hill, said the chances we'll see…

London: An experimental vaccine developed by researchers at Oxford University has shown promise in preventing COVID-19, according to a small trial in six monkeys. The vaccine candidate, ChAdOx1 nCoV-19, is currently being tested in humans too. Over 1,000 volunteers have participated in the clinical trials. The results of the trial in six rhesus macaque monkeys…

In the global race to find a vaccine, Oxford University just jumped way ahead of the pack. Human testing is already underway, and scientists say they're hopeful a coronavirus vaccine will be widely available by September.Technology the lab had already developed in previous work on inoculations for other viruses, including a close relative of COVID-19,…

Microbiologist Elisa Granato gets an injection on Thursday as part of the first human trials in Britain for a potential coronavirus vaccine. Photo: University of Oxford via AP Six animals inoculated with vaccine candidate then exposed to virus did not catch Covid-19 after 28 days Up to 60 million doses could be produced by Serum…